Epigenetic aberrations in myeloid malignancies (Review)

International Journal of Molecular Medicine

Volumn 32, Issue 3, 2013, Pages 532-538

  Takahashi, Shinichiro ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Epigenetic aberrations; Gene mutations; Myeloid malignancies

Indexed keywords

CD135 ANTIGEN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; GENOMIC DNA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN; SEX COMB LIKE 1 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CELL PROLIFERATION; CHROMOSOME 7Q; CHROMOSOME MUTATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; EPIGENETICS; EVENT FREE SURVIVAL; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENOME; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; KARYOTYPE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; NONSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TETRATRICOPEPTIDE REPEAT; TUMOR SUPPRESSOR GENE; UNIPARENTAL DISOMY; X CHROMOSOME;

ANIMALS; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEMETHYLASES; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID; MUTATION; NUCLEAR PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 84880397170     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1417     Document Type: Review

References (53)

1. Takahashi S: Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol 4: 36, 2011.
2. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066, 2009.
3. Ley TJ, Ding L, Walter MJ, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424-2433, 2010.
4. Figueroa ME, Abdel-Wahab O, Lu C, et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567, 2010.
5. Yan XJ, Xu J, Gu ZH, et al: Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43: 309-315, 2011.
6. Delhommeau F, Dupont S, Della Valle V, et al: Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289-2301, 2009.
7. Metzeler KH, Maharry K, Radmacher MD, et al: TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 29: 1373-1381, 2011.
8. Delhommeau F, Jeziorowska D, Marzac C and Casadevall N: Molecular aspects of myeloproliferative neoplasms. Int J Hematol 91: 165-173, 2010.
9. Ko M, Huang Y, Jankowska AM, et al: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468: 839-843, 2010.
10. Chen Q, Chen Y, Bian C, Fujiki R and Yu X: TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493: 561-564, 2013.
11. Boissel N, Nibourel O, Renneville A, et al: Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 28: 3717-3723, 2010.
12. Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W and Haferlach T: IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 116: 5486-5496, 2010.
13. Reitman ZJ and Yan H: Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102: 932-941, 2010.
14. Duncan CG, Barwick BG, Jin G, et al: A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 22: 2339-2355, 2012.
15. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
16. Wheeler DA, Srinivasan M, Egholm M, et al: The complete genome of an individual by massively parallel DNA sequencing. Nature 452: 872-876, 2008.
17. Lee SW, Cho YS, Na JM, et al: ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 285: 18-29, 2010.
18. Wang J, Hevi S, Kurash JK, et al: The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 41: 125-129, 2009.
19. Gelsi-Boyer V, Trouplin V, Adelaide J, et al: Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145: 788-800, 2009.
20. Abdel-Wahab O, Manshouri T, Patel J, et al: Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70: 447-452, 2010.
21. Chou WC, Huang HH, Hou HA, et al: Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 116: 4086-4094, 2010.
22. Fisher CL, Pineault N, Brookes C, et al: Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115: 38-46, 2010.
23. Tiu RV, Visconte V, Traina F, Schwandt A and Maciejewski JP: Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep 6: 126-135, 2011.
24. Nikoloski G, Langemeijer SM, Kuiper RP, et al: Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42: 665-667, 2010.
25. Ernst T, Chase AJ, Score J, et al: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-726, 2010.
26. Makishima H, Jankowska AM, Tiu RV, et al: Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 24: 1799-1804, 2010.
27. Chase A and Cross NC: Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613-2618, 2011.
28. Jankowska AM, Makishima H, Tiu RV, et al: Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118: 3932-3941, 2011.
29. Sauvageau M and Sauvageau G: Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7: 299-313, 2010.
30. van Haaften G, Dalgliesh GL, Davies H, et al: Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41: 521-523, 2009.
31. Basecke J, Whelan JT, Griesinger F and Bertrand FE: The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol 135: 438-449, 2006.
32. Yu BD, Hess JL, Horning SE, Brown GA and Korsmeyer SJ: Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378: 505-508, 1995.
33. Milne TA, Briggs SD, Brock HW, et al: MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 10: 1107-1117, 2002.
34. Dorrance AM, Liu S, Yuan W, et al: Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest 116: 2707-2716, 2006.
35. Whitman SP, Hackanson B, Liyanarachchi S, et al: DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 112: 2013-2016, 2008.
36. Munoz L, Nomdedeu JF, Villamor N, et al: Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 17: 76-82, 2003.
37. Lugthart S, van Drunen E, van Norden Y, et al: High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111: 4329-4337, 2008.
38. Groschel S, Lugthart S, Schlenk RF, et al: High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 28: 2101-2107
39. Delwel R, Funabiki T, Kreider BL, Morishita K and Ihle JN: Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol 13: 4291-4300, 1993.
40. Matsugi T, Kreider BL, Delwel R, Cleveland JL, Askew DS and Ihle JN: The Evi-1 zinc finger myeloid transforming protein binds to genomic fragments containing (GATA)n sequences. Oncogene 11: 191-198, 1995.
41. Perkins AS, Fishel R, Jenkins NA and Copeland NG: Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol 11: 2665-2674, 1991.
42. Lugthart S, Figueroa ME, Bindels E, et al: Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 117: 234-241, 2011.
43. Boultwood J and Wainscoat JS: Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 138: 3-11, 2007.
44. Figueroa ME, Lugthart S, Li Y, et al: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17: 13-27, 2010.
45. Mueller BU, Pabst T, Osato M, et al: Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100: 998-1007, 2002.
46. Vegesna V, Takeuchi S, Hofmann WK, et al: C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res 26: 451-457, 2002.
47. Lamandin C, Sagot C, Roumier C, et al: Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood 100: 4680-4681, 2002.
48. DeKoter RP and Singh H: Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 288: 1439-1441, 2000.
49. Rosenbauer F, Wagner K, Kutok JL, et al: Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 36: 624-630, 2004.
50. Steidl U, Rosenbauer F, Verhaak RG, et al: Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet 38: 1269-1277, 2006.
51. Suzuki M, Yamada T, Kihara-Negishi F, et al: Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b. Oncogene 25: 2477-2488, 2006.
52. Imoto A, Okada M, Okazaki T, Kitasato H, Harigae H and Takahashi S: Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells. J Biol Chem 285: 10300-10309, 2010.
53. Suzuki S, Nakano H and Takahashi S: Epigenetic regulation of the metallothionein-1A promoter by PU.1 during differentiation of THP-1 cells. Biochem Biophys Res Commun 433: 349-353, 2013.